NCT01123304 - Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions

Melanoma

Interventions

DRUG

MORAb028

1 mg MORAb-028 will be injected at either 1 mg/cm3 per day over 5 days for a total dose of 5 mg for the first cohort and 2 mg/cm3 for the second cohort. Subjects will receive MORAb-028 injections on Days: 1-5, 8-12 and 22-26.

Trial Locations (1)

90404

John Wayne Cancer Institute, Santa Monica